OrbusNeich Announces Favorable Ruling from the European Patent Office and Initiation of Litigation Against Terumo Corporation

PR61067

HONG KONG and FT LAUDERDALE, Florida, July 1 /PRN=KYODO JBN/ --

OrbusNeich Medical, Inc. ("OrbusNeich"), a designer, developer, manufacturer

and marketer of innovative medical devices for the treatment of vascular

diseases, announced today that on May 13, 2015, it prevailed in a final

opposition appeal hearing in the European Patent Office ("EPO") regarding

European Patent EP 1 341 482 - STENT HAVING HELICAL ELEMENTS ('482). The '482

patent has withstood the highest level of review in the EPO and has been upheld

as a valid patent in amended form.

In a related matter, OrbusNeich announced that it had filed suit in Germany in

the District Court Dusseldorf and in the Netherlands regarding patent

infringement of the '482 patent by Terumo and their Ultimaster[TM] Drug Eluting

Stent. A request for a preliminary injunction banning distribution of the

Ultimaster Drug Eluting Stent has been filed in Germany.

"Our intellectual property represents the creativity of OrbusNeich employees.

We have spent considerable resources creating our IP portfolio which is one of

the base assets of companies operating in this industry. We don't view

ourselves as a particularly litigious company, but as we have demonstrated in

the past, we will vigorously defend our intellectual property." said Wayne

Johnson, President and Chief Executive Officer of OrbusNeich.  

About OrbusNeich - Pioneers in life-changing technologies

OrbusNeich is a global pioneer in the provision of life-changing vascular

solutions and offers an extensive portfolio of products that set industry

benchmarks in vascular intervention. Current products are the world's first

dual therapy stent, the COMBO Dual Therapy Stent, and the world's first

pro-healing stent, the Genous(TM) Stent. Other products include stents and

balloons marketed under the names of Azule(TM), R Stent(TM), Scoreflex(TM), Sapphire(TM)

II, Sapphire(TM) II Pro and Sapphire(TM) II NC. OrbusNeich is headquartered in Hong

Kong and has operations in Shenzhen, China; Fort Lauderdale, Florida, USA.;

Hoevelaken, The Netherlands; and Tokyo, Japan. OrbusNeich supplies medical

devices to interventional cardiologists in more than 60 countries. For more

information, visit http://www.OrbusNeich.com.

Learn more about our life-changing technologies on our social media channels:

Twitter: http://www.twitter.com/OrbusNeich

LinkedIn: http://www.linkedin.com/company/orbusneich-medical

YouTube: http://www.youtube.com/user/OrbusNeichMedia

Source: OrbusNeich Medical, Inc.